Conflict of interest: J-L. Pépin is supported by the French National Research Agency in the framework of the “Investissements d’avenir” programme (ANR-15-IDEX-02) and the “e-health and integrated care and trajectories medicine and MIAI artificial intelligence” chairs of excellence from the Grenoble Alpes University Foundation; this work has been partially supported by MIAI @ university Grenoble Alpes (ANR-19-P3IA-0003); J-L. Pépin has received lecture fees or conference travel grants from ResMed, Philips, AstraZeneca, Jazz Pharmaceuticals, Agiradom and Bioprojet, and has received unrestricted research funding from ResMed, Philips, GlaxoSmithKline, Bioprojet, Fondation de la Recherche Medicale (Foundation for Medical Research), Direction de la Recherche Clinique du CHU de Grenoble (Research Branch Clinic CHU de Grenoble), and fond de dotation “Agir pour les Maladies Chroniques” (endowment fund “Acting for Chronic Diseases”). W. Randerath reports participation on an advisory board for Bioprojet and Procter & Gamble (consultancy), speaking fees and travel grants from Bioprojet, Heinen & Löwenstein, Habel Medizintechnik, Jazz Pharmaceutical, Philips Respironics and Westfalen Medical.